SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Quantifying factors for the success of stratified medicine · Study

ReviewQuantifying factors for the success of stratified medicine

Mark R. Trusheim2011

Review2011

Quantifying factors for the success of stratified medicine

Mark R. Trusheim · Breon Burgess · Sean Xinghua Hu · Theresa Long · Steven D. Averbuch · Aiden A. Flynn +8 more

102 citations·0/0 files stored·Nature Reviews Drug Discovery

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Health Systems, Economic Evaluations, Quality of Life Pharmaceutical Economics and Policy Statistical Methods in Clinical Trials

Abstract

No abstract was published for this record.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 102 citations exist upstream.

References

2007Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers 2007Realizing the promise of personalized medicine.2009The microeconomics of personalized medicine: today's challenge and tomorrow's promise 2006Diagnostics and biomarker development: priming the pipeline 2002Priming the pipeline

Cited by

2025Handbook of Decision Analysis 2016The Historical and Current Concepts of “Plain” Interest Rates, Forward Rates and Discount Rates Are or Can Be Misleading

Related works

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

2018Whole-Brain Multimodal Neuroimaging Model Using Serotonin Receptor Maps Explains Non-linear Functional Effects of LSDarticle · 1 shared reference 2015From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patientsarticle · 1 shared reference 2016What Constitutes “Good” Evidence for Public Health and Social Policy-making? From Hierarchies to Appropriatenessarticle · 1 shared reference 2012Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?article · 1 shared reference 2012Orphan drug development: an economically viable strategy for biopharma R&Darticle · 1 shared reference 2013Advancing the Responsible Use of Medicines: Applying Levers for Changepreprint · 1 shared reference

Details

Year2011

Typereview

Published2011-10-31

VenueNature Reviews Drug Discovery

ISSN-L1474-1776

Languageen

Citations102

Files0 public / 0

ShelfHealth Systems, Economic Evaluations, Quality of Life

Identifiers

doi10.1038/nrd3557

openalex_workW1986403099

Links

Imported from OpenAlex (CC0) — nothing here is generated.